All In Biotech

Drug Trial Radar · NCT05947500

Testing the Combination of Two Anticancer Drugs M1774 (Tuvusertib) and Avelumab to Evaluate Their Safety and Effectiveness in Treating Merkel Cell Skin Cancer, MATRiX Trial

A Randomized Phase 2 Study of ATR Inhibition in Advanced PD-(L)1-Refractory Merkel Cell Carcinoma: The MATRiX Trial

Last checked: Nov 19, 2026Latest source record: Jul 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

May 21, 2024

Primary completion

Jan 1, 2028

Study completion Jan 1, 2028

Sponsor

Sponsor type
NIH
First posted
Jul 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial compares tuvusertib in combination with avelumab to tuvusertib alone to determine whether the combination therapy will lengthen the time before the cancer starts getting worse in patients with Merkel cell cancer that has not responded to previous treatment (refractory). Tuvusertib is a drug that inhibits an enzyme called ataxia telangiectasia and Rad3 related (ATR) kinase, which is an enzyme that plays a role in repair of damaged deoxyribonucleic acid (DNA) as well as tumor cell replication and survival. It may lead to tumor cell death by inhibiting ATR kinase activity. Immunotherapy with monoclonal antibodies, such as avelumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving tuvusertib in combination with avelumab may lengthen the time before Merkel cell cancer starts getting worse compared to giving avelumab alone.

Conditions

  • Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8
  • Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8
  • Locally Advanced Merkel Cell Carcinoma
  • Metastatic Merkel Cell Carcinoma
  • Refractory Merkel Cell Carcinoma
  • Unresectable Merkel Cell Carcinoma

Interventions

  • AvelumabDrug

    Given IV

  • Biopsy ProcedureProcedure

    Undergo biopsy

  • Biospecimen CollectionProcedure

    Undergo collection of blood and stool

  • Computed TomographyProcedure

    Undergo CT or PET/CT

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • Positron Emission TomographyProcedure

    Undergo PET/CT

  • TuvusertibDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite progression-free survival (PFS)Time frame: From registration to progressive disease or death whichever occurs first, assessed up to 2 years

Locations

51 sites in 2 countries. Site status is shown where the registry gives one.

  • UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

    Irvine, California

  • UC San Diego Moores Cancer Center

    La Jolla, California

  • Keck Medicine of USC Koreatown

    Los Angeles, California

  • Los Angeles General Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • USC Norris Oncology/Hematology-Newport Beach

    Newport Beach, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • UCHealth University of Colorado Hospital

    Aurora, Colorado

  • Yale University

    New Haven, Connecticut

  • Sibley Memorial Hospital

    Washington D.C., District of Columbia

  • UM Sylvester Comprehensive Cancer Center at Aventura

    Aventura, Florida

  • UM Sylvester Comprehensive Cancer Center at Coral Gables

    Coral Gables, Florida

  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach

    Deerfield Beach, Florida

  • University of Miami Miller School of Medicine-Sylvester Cancer Center

    Miami, Florida

  • UM Sylvester Comprehensive Cancer Center at Kendall

    Miami, Florida

  • UM Sylvester Comprehensive Cancer Center at Plantation

    Plantation, Florida

  • Moffitt Cancer Center - McKinley Campus

    Tampa, Florida

  • Moffitt Cancer Center

    Tampa, Florida

  • Emory University Hospital/Winship Cancer Institute

    Atlanta, Georgia

  • Northwestern University

    Chicago, Illinois

  • Memorial Hospital East

    Shiloh, Illinois

  • HaysMed

    Hays, Kansas

  • University of Kansas Cancer Center

    Kansas City, Kansas

  • Lawrence Memorial Hospital

    Lawrence, Kansas

  • The University of Kansas Cancer Center - Olathe

    Olathe, Kansas

  • University of Kansas Cancer Center-Overland Park

    Overland Park, Kansas

  • University of Kansas Hospital-Indian Creek Campus

    Overland Park, Kansas

  • Salina Regional Health Center

    Salina, Kansas

  • University of Kansas Health System Saint Francis Campus

    Topeka, Kansas

  • University of Kansas Hospital-Westwood Cancer Center

    Westwood, Kansas

  • Johns Hopkins University/Sidney Kimmel Cancer Center

    Baltimore, Maryland

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • Siteman Cancer Center at Saint Peters Hospital

    City of Saint Peters, Missouri

  • Siteman Cancer Center at West County Hospital

    Creve Coeur, Missouri

  • University Health Truman Medical Center

    Kansas City, Missouri

  • University of Kansas Cancer Center - North

    Kansas City, Missouri

  • University of Kansas Cancer Center - Lee's Summit

    Lee's Summit, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Siteman Cancer Center-South County

    St Louis, Missouri

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.